Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.